Apogenix Receives FDA Orphan Drug Designation For Apocept(TM) To Treat Myelodysplastic Syndromes And Initiates Clinical Phase I Study

Apogenix GmbH, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, announced today that its lead product, Apocept(TM) (APG101), has been granted orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of Myelodysplastic syndromes (MDS). MDS are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis leading to blood cytopenias, especially anemia...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Cancer / Oncology Source Type: news